rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Attovia Therapeutics, Inc.

ATTO · Nasdaq

Health CareBiotechnology

We hold no 150-day reading for ATTO yet: it needs about 200 sessions of history. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
not in the set
Weeks in an uptrend
—
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$145.9M
Insider sales, 12 months
$18.0M
Officials’ trades on record
0
Institutions holding
0

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 0 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$140.0MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months18
Sale orders, 12 months6
Buyers · sellers10 · 4
WhoDidSharesTraded
Goldman Sachs Group IncOtherbought500,000at $17.006 Aug 2026filed 13 Aug 2026
Goldman Sachs Group IncOtherbought500,000at $17.006 Aug 2026filed 28 Aug 2026
Venbio Global Strategic Fund Iv, L.p.10% ownerbought382,352at $17.006 Aug 2026filed 10 Aug 2026
Redmile Group, Llc10% ownerbought200,000at $17.006 Aug 2026filed 7 Aug 2026
Redmile Group, Llc10% ownerbought400,000at $17.006 Aug 2026filed 7 Aug 2026
Sanofi10% ownerbought300,000at $17.006 Aug 2026filed 7 Aug 2026
Frazier Life Sciences Xi, L.p.10% ownerbought588,235at $17.006 Aug 2026filed 6 Aug 2026
Colin WalshDirectorbought500,000at $17.006 Aug 2026filed 13 Aug 2026
Colin WalshDirectorbought500,000at $17.006 Aug 2026filed 28 Aug 2026
Goldman Sachs Group IncOtherbought85,000at $21.005 Aug 2026filed 13 Aug 2026
Goldman Sachs Group IncOthersold988at $22.035 Aug 2026filed 13 Aug 2026
Goldman Sachs Group IncOthersold447at $21.875 Aug 2026filed 13 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders0
New · exited0 · 0
Reported value$0

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange

Everyone who traded it

Colin Walsh Company insiderDirector · last 6 Aug 20264 · 2
Deep Track Biotechnology Master Fund, Ltd. Company insider10% owner · last 6 Aug 20260 · 0
Fhmls Xi, L.p. Company insider10% owner · last 6 Aug 20261 · 0
Frazier Life Sciences XI, L.P. Company insider10% owner · last 6 Aug 20261 · 0
Goldman Sachs & Co. Llc Company insiderOther · last 6 Aug 20262 · 1
Goldman Sachs Asset Management, L.p. Company insiderOther · last 6 Aug 20262 · 1
GOLDMAN SACHS GROUP INC Company insiderOther · last 6 Aug 20264 · 2
Jeremy Green Company insider10% owner · last 6 Aug 20261 · 0
Redmile Group, LLC Company insider10% owner · last 6 Aug 20261 · 0
Sanofi Company insider10% owner · last 6 Aug 20261 · 0
venBio Global Strategic Fund IV, L.P. Company insider10% owner · last 6 Aug 20261 · 0
Angie You Company insiderDirector · last 4 Aug 20260 · 0

Same industry

No other stock in its industry this week.

Government contracts

No federal award is tied to it.

From its SEC filings

No ratio computed from its SEC filings yet.

Analyst forecasts

No analyst forecasts yet.